Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

Do you have an advanced melanoma tumor and have received prior systemic therapy? Has your cancer progressed on the other treatments? If so, the you may be able to take part in a study to help us learn the safety and dosage of the drug AB248 on solid tumors.

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Have you been diagnosed with metastatic triple negative breast cancer and have had progression of your cancer during or following your most recent cancer treatment? If so, you may be eligible for a study looking at the combination of two investigational drugs with doxil for patients with metastatic triple negative breast cancer.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

The purpose of this study is to learn about the effects of a research investigational product, CT-0525, and to see if CT-0525 is safe for participants with advanced cancer. This study is the first time that CT-0525 will be given to humans. CT-0525 is a special kind of product that is made of blood cells taken from your own body. Once collected, these blood cells will be altered and infused back into your body.

Have you been diagnosed with Metastatic Castration-Resistant Prostate Cancer (mCRPC)? If so, you may be able to take part in a research study investigating if the study drug together with standard of care drug are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with standard of care alone.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Are you premenopausal and have been diagnosed with ER-positive, HER2-negative breast cancer and had surgery for your breast cancer? If so, you may be able to take part in a research study evaluating the addition of chemotherapy given after breast surgery with ovarian suppression and endocrine therapy versus ovarian suppression and endocrine therapy alone.